In this sponsored episode of Podnosis, experts examine how molecular residual disease testing is transforming how clinicians assess recurrence risk in triple-negative breast cancer. Drawing on new data from the NSABP B-59 substudy presented at SABCS and AACR, the discussion highlights how circulating tumor DNA is providing earlier and more precise insight into patient outcomes.

Dr. Priya Rastogi, chief medical officer of the NSABP Foundation, explains how MRD testing can detect residual disease that standard tools may miss, often months or years before clinical recurrence. The conversation explores key findings, including the strong correlation between post-surgical ctDNA positivity and recurrence risk, as well as the prognostic value of ctDNA status earlier in the treatment pathway.